BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

About this update from Billiontoone, Inc.

Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisions MENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology. Dr. Dmitrovsky will lead medical strategy for BillionToOne's Northstar liquid biopsy portfolio as it enters its next phase of growth, expanding its clinical adoption in guiding treatment decisions for patients with solid tumors and leading the company's entry into the minimal residual disease (MRD) space. Dr. Dmitrovsky has shaped cancer research and care at some of the country's most respected institutions for more than two decades. He joins BillionToOne from the Frederick National Laboratory for Cancer Research, where he served as Laboratory Director and President of Leidos Biomedical Research. He previously served as Provost and Executive Vice President at the University of Texas MD Anderson Cancer Center and as Professor and Chair of Pharmacology and Toxicology at Dartmouth's Geisel School of Medicine. He graduated magna cum laude in Biochemical Sciences from Harvard University and received his medical degree from Cornell University Medical College, completing a residency in Internal Medicine at New York Hospital, Memorial Sloan Kettering Cancer Center, and an oncology fellowship at the National Cancer Institute. His work has repeatedly moved from the bench to the clinic, including establishing curative all-trans-retinoic acid-based differentiation therapy for acute promyelocytic leukemia, work reported in the New England Journal of Medicine that led to the therapy's FDA approval. He was recognized with selection as an American Cancer Society Professor and election as a fellow of the American Association for the Advancement of Science. "My career has always centered on closing the gap between scientific discovery and patient care," said Dr. Dmitrovsky. "BillionToOne's Northstar platform represents exactly that kind of opportunity, giving oncologists tools...

View stock analysis, news, and events for Billiontoone, Inc.